Immunogen (IMGN) Misses Q2 EPS by 1c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.39), $0.01 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $13.85 million versus the consensus estimate of $18.1 million.

For 2017, ImmunoGen expects:

• revenues between $70 million and $75 million, which includes $28 million of expected upfront and milestone fees from our partners;
• operating expenses between $175 million and $180 million; and
• cash and marketable securities at December 31, 2017 between $35 million and $40 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79